Long-Term Outcomes of Ruxolitinib Therapy in Patients With cGVHD
A panelist discusses how identifying steroid-dependent or steroid-refractory (SR) graft-vs-host disease (GVHD) requires careful clinical monitoring, with the determination typically made when patients show disease progression during prednisone taper, inadequate response after 5 to 7 days of treatment, or persistent disease despite 2 weeks of appropriate steroid therapy.
Video content above is prompted by the following:
- Moving into steroid-dependent or SR cases, how do you determine a treatment approach?
- Please discuss efficacy and safety from REACH3 3-year final analysis.
- What are clinical implications from the failure-free survival and duration of response data?
- How has your clinical practice adapted given these data?
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
